- Home
- TMQ vs SGP Comparison
TMQ vs SGP Comparison
Compare TMQ & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMQ | SGP |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | Canada | United States |
| Employees | N/A | 65 |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.7M | 650.9M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | TMQ | SGP |
|---|---|---|
| Price | $3.31 | $19.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 2.3M | 64.9K |
| Earning Date | 04-02-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $17.06 |
| 52 Week High | $11.29 | $30.56 |
Technical Indicators
Market Signals| Indicator | TMQ | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 32.91 | 47.01 |
| Support Level | $2.00 | $17.60 |
| Resistance Level | $4.98 | $20.25 |
| Average True Range (ATR) | 0.25 | 1.15 |
| MACD | -0.07 | 0.30 |
| Stochastic Oscillator | 1.08 | 71.29 |
Price Performance
Historical ComparisonAbout TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.